Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656932 | 0.91 | OPRM1 (0.46) | ALDH1A1LMNAHTR4DRD2HTR2A | |
| SCHEMBL5656321 | 0.87 | HTR4 (0.49) | ALDH1A1HTR4DRD2HTR2AKDM4E | |
| SCHEMBL5659379 | 0.85 | LMNA (0.44) | ALDH1A1LMNAHTR4DRD4OPRM1 | |
| SCHEMBL5656351 | 0.84 | HTR1A (0.57) | ALDH1A1DRD2HTR2AKDM4ESMN1; SMN2 | |
| SCHEMBL5654725 | 0.83 | DRD2 (0.55) | ALDH1A1DRD2HTR2AKDM4ETDP1 | |
| SCHEMBL5657861 | 0.83 | OPRM1 (0.55) | ALDH1A1HTR4DRD2HTR2AKDM4E | |
| SCHEMBL5655983 | 0.82 | MAPT (0.53) | DRD2HTR2ADRD4DRD3OPRM1 | |
| SCHEMBL5659495 | 0.82 | OPRM1 (0.50) | ALDH1A1DRD2HTR2AKDM4ETDP1 | |
| SCHEMBL5657431 | 0.82 | LMNA (0.53) | ALDH1A1LMNAHTR4DRD2HTR2A | |
| SCHEMBL5655837 | 0.82 | DRD2 (0.63) | ALDH1A1DRD2HTR2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | ALDH1A1 1018/4885LMNA 1137/4885HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.